Pfizer Inc. $PFE Shares Sold by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 5.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 116,895 shares of the biopharmaceutical company’s stock after selling 7,070 shares during the quarter. Murphy Pohlad Asset Management LLC’s holdings in Pfizer were worth $2,834,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Brighton Jones LLC raised its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after purchasing an additional 618,117 shares during the last quarter. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Koshinski Asset Management Inc. raised its stake in Pfizer by 9.4% in the 1st quarter. Koshinski Asset Management Inc. now owns 23,208 shares of the biopharmaceutical company’s stock valued at $588,000 after purchasing an additional 1,995 shares during the last quarter. Mather Group LLC. increased its stake in shares of Pfizer by 9.8% during the 1st quarter. Mather Group LLC. now owns 22,185 shares of the biopharmaceutical company’s stock valued at $562,000 after acquiring an additional 1,978 shares during the last quarter. Finally, DAVENPORT & Co LLC increased its stake in shares of Pfizer by 16.1% during the 1st quarter. DAVENPORT & Co LLC now owns 378,669 shares of the biopharmaceutical company’s stock valued at $9,594,000 after acquiring an additional 52,497 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. UBS Group reaffirmed a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Morgan Stanley dropped their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.13.

Pfizer Stock Up 0.0%

Shares of NYSE:PFE opened at $24.30 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.64. The stock has a market capitalization of $138.15 billion, a P/E ratio of 12.93, a PEG ratio of 0.81 and a beta of 0.55. The stock has a 50-day simple moving average of $24.80 and a 200-day simple moving average of $24.25.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the previous year, the business earned $0.60 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.1%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.